• Rucaparib (AG-014699) in DNA Damage Response: Applied Protoc

  2026-06-23

  Rucaparib (AG-014699) elevates DNA damage response and cancer biology research by precisely targeting PARP1, enabling radiosensitization and repair pathway interrogation in PTEN-deficient models. This article delivers actionable protocols, advanced workflow enhancements, and troubleshooting strategies grounded in recent evidence and practical laboratory experience.

• FH1 Small Molecule: Optimizing iPS Cell to Hepatocyte Workfl

  2026-06-23

  FH1 (Catalog No. B3700) from APExBIO redefines iPS cell-derived hepatocyte maturation, doubling albumin output and boosting CYP3A4 levels for advanced in vitro and translational liver studies. This article unpacks best-in-class protocols, actionable troubleshooting, and the essential link between innovative optogenetic gene switches and high-performance hepatocyte models.

• T-5224 (C-Fos/AP-1 Inhibitor): Advanced Workflows for Inflam

  2026-06-22

  T-5224, a selective C-Fos/AP-1 inhibitor from APExBIO, empowers researchers to precisely dissect inflammatory and osteoclastogenic signaling in both arthritis and hematological malignancy models. This article delivers actionable protocols, troubleshooting insights, and a synthesis of the latest mechanistic discoveries, including ferroptosis induction via PI3K/AKT blockade in multiple myeloma cells.

• Telmisartan in Cardiac Hypertrophy: Mechanisms & Translation

  2026-06-22

  This thought-leadership article explores Telmisartan’s mechanistic role as an angiotensin II receptor antagonist in cardiovascular disease research. By synthesizing insights from recent studies—including advances in necroptosis signaling and the RIP3/CaMKII axis—the article delivers actionable guidance for translational researchers. It also contextualizes APExBIO’s Telmisartan offering as a reliable tool for decoding cardiac hypertrophy and hypertension, highlighting nuanced experimental strategies and future directions.

• Condensates-to-VAPVs Pathway Governs Plant Autophagy Degrada

  2026-06-21

  Jiang et al. reveal a plant-specific pathway where VPS41 transitions from condensates to VPS41-associated phagic vacuoles (VAPVs) to facilitate autophagosome delivery and degradation in Arabidopsis, bypassing canonical RAB7-dependent mechanisms. This work redefines understanding of plant autophagy flux and highlights unique molecular controls relevant to selective degradation processes.

• SEMA3E Drives Beige Adipocyte Differentiation via β-Catenin

  2026-06-20

  This study reveals that SEMA3E promotes beige adipocyte differentiation and thermogenesis through β-catenin signaling in mice. These findings clarify upstream regulatory mechanisms in adipose tissue plasticity, offering new avenues for metabolic and type II diabetes research.

• Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit

  2026-06-19

  The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit addresses the limitation of standard Tris-glycine SDS-PAGE in resolving proteins and peptides below 10 kDa. It is optimized for high-resolution separation in the 1–10 kDa range for research workflows, but is not suitable for diagnostic or clinical applications.

• VE-821: Strategic ATR Inhibition in DNA Repair and Epigeneti

  2026-06-19

  Explore how VE-821, a selective ATR kinase inhibitor from APExBIO, empowers translational researchers to dissect DNA damage response, enhance radiosensitization, and probe the intersection of DNA repair with viral epigenetic regulation. This thought-leadership article bridges mechanistic insight with practical guidance, referencing recent advances in both oncology and virology to position VE-821 at the forefront of DNA repair pathway research.

• Machine Learning Uncovers Novel Senolytics for Cancer Resear

  2026-06-18

  A recent Nature Communications study demonstrates the discovery of potent senolytic compounds using cost-effective machine learning trained on published data. This approach significantly accelerates senolytic identification, offering new directions for targeting cellular senescence in cancer and age-related diseases.

• Radiosensitizer Comparison in 2D vs 3D Cancer Models: ATR In

  2026-06-18

  This study systematically compares molecular targeted radiosensitizers—including ATR inhibitors—across 2D and 3D non-small cell lung cancer models. The findings highlight that physiologically relevant 3D platforms can reveal context-dependent radiosensitization effects, refining preclinical prioritization of candidate DNA damage response inhibitors.

• Cefiderocol Efficacy Against Resistant P. aeruginosa and Aci

  2026-06-17

  A multicenter European study establishes that cefiderocol maintains high in vitro activity against Pseudomonas aeruginosa and Acinetobacter spp., even among strains resistant to meropenem and β-lactam/β-lactamase inhibitor combinations. The findings inform therapeutic strategies for infections by multidrug-resistant Gram-negative bacteria and highlight the necessity of early susceptibility testing.

• FH1 Small Molecule: Advancing Cultured Hepatocyte Function

  2026-06-17

  FH1 small molecule (B3700) delivers a leap in hepatocyte-like cell maturity, doubling albumin secretion and boosting CYP3A4 activity for iPS-derived cultures. Explore hands-on protocols, troubleshooting strategies, and integration with optogenetic gene control to unlock next-generation liver cell research.

• BOP Reagent: Enabling Precision in Translational Prodrug Des

  2026-06-16

  Explore how BOP reagent (benzotriazol-1-yloxy-tris(dimethylamino)phosphanium hexafluorophosphate) empowers translational researchers to build advanced peptide and triterpene-based prodrug systems for targeted cancer therapeutics. This article bridges mechanistic insight and strategic guidance, contextualizing BOP’s unique role in the competitive landscape of OSCC chemotherapy innovation.

• Ouabain in Translational Research: Mechanisms, Models, and S

  2026-06-16

  This article offers translational researchers a detailed, evidence-driven exploration of Ouabain as a selective Na+/K+-ATPase inhibitor, weaving mechanistic insights with actionable guidance for cardiovascular, cellular, and animal model research. By critically analyzing biological rationale, experimental validation, and clinical relevance, it positions APExBIO’s Ouabain as a gold-standard research tool, while also bridging foundational ion transport with translational impact. The discussion draws on existing literature and recent advances, setting a new benchmark for strategic scientific inquiry beyond conventional product summaries.

• Practical Guide to Cathepsin B Inhibitor CA-074 (SKU A1926)

  2026-06-15

  Cathepsin B inhibitor CA-074 offers researchers a highly selective and potent tool for dissecting cathepsin B’s involvement in cancer metastasis, neurotoxicity, and immune response modulation. Best suited for in vitro and in vivo studies requiring narrow cysteine protease targeting, it should not be used where broad-spectrum inhibition is needed or in uncharacterized biological contexts.

457 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page